Comparable effectiveness using flexible single-dose GnRH antagonist (cetrorelix) and single-dose long GnRH agonist (goserelin) protocol for IVF cycles--a prospective, randomized study.
This prospective randomized study compared the effectiveness of a flexible single-dose gonadotrophin-releasing hormone (GnRH) antagonist (cetrorelix) and a single-dose long GnRH agonist (goserelin) protocol for ovarian stimulation in IVF/intracytoplasmic sperm injection (ICSI) cycles. All patients from the waiting list were successively included in the study, pre-programmed with an oral contraceptive, and randomized into goserelin and cetrorelix groups. Depending on the date on which their menstrual period started, patients took oral contraceptives for one or two cycles. Ultimately, 236 patients in the first group received a single dose of depot preparation of goserelin and 224 patients received a single 3 mg dose of cetrorelix in the late follicular phase, when the mean follicle diameter exceeded 12 mm. The mean number of ampoules of FSH and the duration of stimulation was statistically significantly lower in the cetrorelix group than in the goserelin group (25.9 versus 34.5, and 9.6 versus 12.2 days, P < 0.01). The mean number of oocytes retrieved was similar (6.7 +/- 4.5 versus 7.2 +/- 4.6, NS). Similar results were observed in fertilization rates, blastulation rates and blastocyst transfer rates in both groups. Clinical pregnancy and delivery rates per cycle were higher in the goserelin group (34.3 and 30.1%) than in the cetrorelix group (31.9 and 28.3%), but the differences were not statistically significant. The flexible single-dose GnRH antagonist protocol is an advantageous alternative to the long GnRH agonist protocol, with similar efficacy, shorter duration, a significant reduction in the number of FSH ampoules used and without the menopause-like effects of the GnRH antagonist.
Vlaisavljevic
Veljko
V
Department of Reproductive Medicine and Gynaecologic Endocrinology, Maribor Teaching Hospital, Ljubljanska 5, SI-2000 Maribor, Slovenia. vlai@sb-mb.si
Reljic
Milan
M
Lovrec
Vida Gavric
VG
Kovacic
Borut
B
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D004624:Embryo Transfer; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods*; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage* / Q000819:agonists / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors; D017273:Goserelin / Q000008:administration & dosage*; D006727:Hormone Antagonists / Q000008:administration & dosage*; D006801:Humans; D007279:Injections, Subcutaneous; D011247:Pregnancy; D011256:Pregnancy Outcome; D018873:Pregnancy Rate; D011446:Prospective Studies
D018931:Antineoplastic Agents, Hormonal; D006727:Hormone Antagonists; D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone; C062876:cetrorelix